[go: up one dir, main page]

IL146005A0 - Treatment of autoimmune diseases with antagonists which bind to b cell surface markers - Google Patents

Treatment of autoimmune diseases with antagonists which bind to b cell surface markers

Info

Publication number
IL146005A0
IL146005A0 IL14600500A IL14600500A IL146005A0 IL 146005 A0 IL146005 A0 IL 146005A0 IL 14600500 A IL14600500 A IL 14600500A IL 14600500 A IL14600500 A IL 14600500A IL 146005 A0 IL146005 A0 IL 146005A0
Authority
IL
Israel
Prior art keywords
antagonists
bind
cell surface
autoimmune diseases
treatment
Prior art date
Application number
IL14600500A
Other languages
English (en)
Original Assignee
Genentech Inc
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26830960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146005(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Idec Pharma Corp filed Critical Genentech Inc
Publication of IL146005A0 publication Critical patent/IL146005A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
IL14600500A 1999-05-07 2000-05-04 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers IL146005A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13301899P 1999-05-07 1999-05-07
US13962199P 1999-06-17 1999-06-17
PCT/US2000/040018 WO2000067796A1 (en) 1999-05-07 2000-05-04 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers

Publications (1)

Publication Number Publication Date
IL146005A0 true IL146005A0 (en) 2002-07-25

Family

ID=26830960

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14600500A IL146005A0 (en) 1999-05-07 2000-05-04 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers

Country Status (21)

Country Link
US (12) US7820161B1 (de)
EP (3) EP1176981B1 (de)
JP (5) JP2002544174A (de)
KR (2) KR20080039550A (de)
CN (1) CN100358577C (de)
AT (1) ATE311199T1 (de)
AU (2) AU777970C (de)
BR (1) BR0011197A (de)
CA (3) CA2944644C (de)
CY (1) CY1105295T1 (de)
DE (1) DE60024436T2 (de)
DK (1) DK1176981T3 (de)
ES (1) ES2254174T3 (de)
HK (1) HK1043312B (de)
HU (1) HUP0201009A2 (de)
IL (1) IL146005A0 (de)
MX (1) MXPA01011279A (de)
NO (1) NO20015417L (de)
NZ (1) NZ514914A (de)
PL (1) PL200134B1 (de)
WO (1) WO2000067796A1 (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176981B1 (de) 1999-05-07 2005-11-30 Genentech, Inc. Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
SI1176981T1 (sl) 1999-05-07 2006-04-30 Genentech Inc Zdravljenje avtoimunskih bolezni z antagonisti, ki se vezejo na B celicne povrsinske markerje
DE05075555T1 (de) * 1999-06-09 2007-02-08 Immunomedics, Inc. Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1299128A2 (de) * 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Kaltes anti-cd20 antikörper/radiomarkiertes anti-cd22 antikörper kombination
DK2283861T3 (en) * 2000-11-20 2016-02-15 Canadian Blood Services METHOD OF TREATING TROMBOCYTOPENIA WITH MONOCLONAL IVIG
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
CN100488981C (zh) 2001-08-24 2009-05-20 维多利亚大学创新和发展公司 含有蛋白酶激活序列的气单胞菌溶素原及其应用
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
JP2005526044A (ja) 2002-02-21 2005-09-02 デューク ユニバーシティ 抗ｃｄ２２抗体を使用した治療方法
EP2865688A1 (de) * 2002-03-01 2015-04-29 Immunomedics, Inc. Internalisierung von Anti-CD74-Antikörpern und Verfahren zur Verwendung
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
ATE491803T1 (de) 2002-04-23 2011-01-15 Cargill Inc Polypeptide und biosynthetische pfade
EP1389480A1 (de) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutische Anwendung von Guanylhydrazone zur Hemmung von CD83 abhängige Verfahren und Reifung der dendritischen Zellen
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
EP1422241A1 (de) 2002-11-19 2004-05-26 Alexander Steinkasserer Verwendung der löslichen Formen des CD83 und dafür kodierender Nukleinsäuren zur Behandlung oder Vorbeugung von Krankheiten
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
RS20100366A (sr) 2002-12-16 2011-04-30 Genentech, Inc. Varijante imunoglobulina i njihova upotreba
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2003209753A1 (en) * 2003-01-27 2004-08-23 Crucell Holland B.V. Internalising human binding molecules against cd72
KR101092171B1 (ko) 2003-04-09 2011-12-13 제넨테크, 인크. Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는환자에서의 자가면역 질환의 치료법
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004256042A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
DK1662007T3 (da) * 2003-08-28 2011-06-14 Dainippon Sumitomo Pharma Co Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel
RU2006117353A (ru) 2003-10-21 2007-12-27 Карджилл, Инкорпорейтед (Us) Получение монатина и предшественников монатина
HUE042914T2 (hu) * 2003-11-05 2019-07-29 Roche Glycart Ag CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval
EP1696955A2 (de) * 2003-12-19 2006-09-06 Genentech, Inc. Nachweis von cd20 in der therapie von autoimmunkrankheiten
EP1570857A1 (de) * 2004-02-27 2005-09-07 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verfahren zur Inhibierung der transepithelialen Migration von Leukozyten oder Tumorzellen durch eine CD81-bindende Substanz und dessen Verwendungen
EP1740946B1 (de) 2004-04-20 2013-11-06 Genmab A/S Humane monoklonale antikörper gegen cd20
JP2007536246A (ja) * 2004-05-05 2007-12-13 ジェネンテック・インコーポレーテッド 自己免疫疾患の予防法
RU2396980C2 (ru) * 2004-06-04 2010-08-20 Дженентек, Инк. Способ лечения волчанки
BRPI0510915A (pt) * 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
EP1786831A4 (de) 2004-07-30 2008-01-23 Cargill Inc Alanin-2,3-aminomutasen
PL2213683T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
CN101087807A (zh) * 2004-10-05 2007-12-12 健泰科生物技术公司 治疗血管炎的方法
JP5272310B2 (ja) * 2004-10-21 2013-08-28 小野薬品工業株式会社 免疫抑制受容体の用途
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
PL1853718T3 (pl) 2005-02-15 2016-01-29 Univ Duke Przeciwciała anty-CD19 i zastosowania w onkologii
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090038023A1 (en) 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
ES2587572T3 (es) 2005-04-26 2016-10-25 Cargill, Incorporated Polipéptidos y rutas biosintéticas para la producción de estereoisómeros de monatina y sus precursores
AU2006251647A1 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
WO2007053184A2 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN101267836A (zh) * 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
US20090226440A1 (en) * 2005-08-12 2009-09-10 Shane Grey Prophylactic and/or Therapeutic Method for Treatment of Autoimmune Disease
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007056867A1 (en) 2005-11-21 2007-05-24 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
EP1999148B8 (de) 2006-03-06 2014-03-05 Medlmmune, LLC Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
EP3153580A3 (de) 2006-03-07 2017-04-19 BASF Enzymes LLC Aldolasen, nukleinsäuren zur codierung davon sowie verfahren zur herstellung und verwendung davon
EP2112227B1 (de) 2006-03-07 2013-05-15 Cargill, Incorporated Aldolasen, Nukleinsäuren zu ihrer Kodierung sowie Verfahren zu ihrer Herstellung und Verwendung
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2044111B1 (de) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting des komplement-faktors h zur krankheitsbehandlung
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2119452T3 (da) * 2006-12-26 2020-04-20 Ct Inmunologia Molecular Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis
CA2682406A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
EP2188302B1 (de) 2007-07-09 2017-11-01 Genentech, Inc. Verhinderung der reduktion der disulfidbindung während der rekombinanten herstellung von polypeptiden
ES2527297T3 (es) 2007-07-31 2015-01-22 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos para CD20 humano y método para utilizar los mismos
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
CA2716919C (en) 2008-03-14 2015-01-20 Biocon Limited An anti-cd6 monoclonal antibody and use thereof
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
RU2390334C1 (ru) * 2008-12-17 2010-05-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ лечения рассеянного склероза
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
EP4088736A1 (de) 2011-10-25 2022-11-16 Prothena Biosciences Limited Humanisierte anti-amyloid-antikörper-formulierungen und verfahren
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015517490A (ja) * 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US9719993B2 (en) 2012-09-11 2017-08-01 Institució Catalana De Recerca I Estudis Avançats Diagnostic method for detecting an autoimmune disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
DK2900277T3 (da) 2012-12-13 2022-04-04 Immunomedics Inc Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet
GB201302597D0 (en) 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015001352A1 (en) 2013-07-03 2015-01-08 The University Court Of The University Of Edinburgh Novel regenerative therapy
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
DK3024485T3 (da) 2013-07-23 2020-12-07 Biocon Ltd Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå
GB201313235D0 (en) 2013-07-24 2013-09-04 Univ Edinburgh Antiviral Compositions Methods and Animals
EP3052106A4 (de) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
GB201318170D0 (en) 2013-10-14 2013-11-27 Univ Edinburgh Proteins with Diagnostic and Therapeutic Uses
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
JP6692343B2 (ja) * 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物としての使用のための抗ｃｄ４５ｒｃ抗体
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
EP3221346B1 (de) 2014-11-21 2020-09-02 Bristol-Myers Squibb Company Antikörper mit modifizierten schweren konstanten regionen
JPWO2016084412A1 (ja) * 2014-11-28 2017-10-05 国立大学法人 東京大学 Ｂ細胞活性化の抑制剤及び自己免疫疾患の治療剤
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
HRP20200640T1 (hr) 2015-05-30 2020-07-10 Molecular Templates, Inc. De-imunizirane, okosnice podjedinice shiga toksina a i molekule koje ciljaju stanice koje ih sadrže
CN120665195A (zh) 2015-06-24 2025-09-19 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
AU2016333512B2 (en) 2015-10-02 2022-11-17 F. Hoffmann-La Roche Ag Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
EP3448260A4 (de) 2016-04-27 2019-10-09 Immunomedics, Inc. Wirksamkeit von anti-trop-2-sn-38-antikörper-wirkstoff-konjugaten zur therapie von rezidivierten/refraktären tumoren gegen checkpoint-inhibitoren
WO2025052171A1 (en) 2016-07-07 2025-03-13 The University Court Of The University Of Edinburgh Alpha-synuclein detection assay
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
CN109844537B (zh) 2016-09-27 2022-06-24 高地和群岛大学 抗原生物标志物
CA3039855A1 (en) 2016-10-21 2018-04-26 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
US10584169B2 (en) 2017-01-24 2020-03-10 I-Mab Biopharma Us Limited Anti-CD73 antibodies and uses thereof
CN110392570A (zh) 2017-03-27 2019-10-29 免疫医疗公司 用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
GB201712952D0 (en) 2017-08-11 2017-09-27 Univ Edinburgh Immunomodulatory agent
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
EA202091710A1 (ru) 2018-03-09 2021-02-16 Агенус Инк. Антитела против cd73 и способы их применения
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
CN112041348B (zh) 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
PL3844189T3 (pl) 2018-08-31 2025-03-31 Regeneron Pharmaceuticals, Inc. Strategia dawkowania, która łagodzi zespół uwalniania cytokin, dla przeciwciał dwuswoistych cd3/cd20
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP4025605A1 (de) 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73-antikörper
EP4084870A1 (de) 2020-01-03 2022-11-09 Incyte Corporation Cd73-inhibitor und a2a/a2b-adenosinrezeptor-inhibitorkombinationstherapie
EP4084825A1 (de) 2020-01-03 2022-11-09 Incyte Corporation Anti-cd73-antikörper und verwendungen davon
CA3207066A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
GB202102931D0 (en) 2021-03-02 2021-04-14 Invizius Ltd Peritoneal fluid composition
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
GB202202728D0 (en) 2022-02-28 2022-04-13 Invizius Ltd Peritoneal fluid composition

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4724213A (en) 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
NZ225599A (en) 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
CA1340565C (en) 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
IL95125A (en) 1989-07-19 1995-07-31 Vandenbark Arthur Allen T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
WO1991013974A1 (en) 1990-03-14 1991-09-19 The Biomembrane Institute Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3048640B2 (ja) 1991-07-25 2000-06-05 アイデック・ファーマシュウティカルズ・コーポレーション ヒトの治療のための組換え抗体
EP0626012B1 (de) 1992-02-11 2003-07-09 Cell Genesys, Inc. Erzielen von homozygotem durch zielgerichtete genetische ereignisse
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5741488A (en) 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
EP0752248B1 (de) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JPH09510952A (ja) * 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
GB9323542D0 (en) 1993-11-15 1994-01-05 Univ Alberta Lymphocyte marker specific for corhn's disease
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
JPH10501815A (ja) 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
WO1996031229A1 (en) 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US20030180290A1 (en) 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US5877299A (en) 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
AU706056B2 (en) 1995-10-13 1999-06-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxin containing a disulfide-stabilized antibody fragment
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1997034633A1 (en) 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
JP2000511539A (ja) 1996-05-31 2000-09-05 ジェネティック・セラピー・インコーポレイテッド 負の選択マーカーをコード化するポリヌクレオチドを含むｔ細胞による対宿主性移植片病の予防
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
JP2000516594A (ja) * 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
ATE233573T1 (de) 1996-10-17 2003-03-15 Immunomedics Inc Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
GB9705744D0 (en) 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DE69737557T2 (de) 1997-12-16 2007-12-20 University Of Zurich Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte
WO1999039726A1 (en) 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in transplantation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020155604A1 (en) 1998-02-19 2002-10-24 Jeffrey A. Ledbetter Compositions and methods for regulating lymphocyte activation
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
TR200003087T2 (tr) 1998-04-21 2001-02-21 Micromet Ag Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
CN1320044A (zh) 1998-08-11 2001-10-31 Idec药物公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
US6555320B1 (en) * 1998-09-01 2003-04-29 Mayo Foundation For Medical Education And Research Methods and materials for evaluating rheumatoid arthritis
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
EP1131093A4 (de) 1998-11-09 2002-05-02 Idec Pharma Corp Behandlung hämatologischer bösartigkeiten assoziiert mit zirkulierenden tumorzellen unter verwendung chimärer anti-cd20 antikörper
KR20010099788A (ko) 1998-11-09 2001-11-09 케네쓰 제이. 울코트 Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
AU766882B2 (en) * 1999-02-25 2003-10-23 National Jewish Medical And Research Center Product and method for treatment of conditions associated with receptor-desensitization
US6383276B1 (en) 1999-03-12 2002-05-07 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
EP1176981B1 (de) 1999-05-07 2005-11-30 Genentech, Inc. Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6404323B1 (en) 1999-05-25 2002-06-11 Varatouch Technology Incorporated Variable resistance devices and methods
DE05075555T1 (de) 1999-06-09 2007-02-08 Immunomedics, Inc. Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
JP2003528805A (ja) 1999-07-12 2003-09-30 ジェネンテック・インコーポレーテッド Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
ATE363290T1 (de) 1999-10-04 2007-06-15 Novartis Vaccines & Diagnostic Cd40 antagonist zur behandlung von psoriasis
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
MXPA02004599A (es) 1999-11-08 2002-10-23 Idec Pharma Corp Tratamiento de tumores malignos de celula b utilizando anticuerpos anti-cd40l en combinacion con anticuerpos anti-cd20 y/o agentes quimioterapeuticos y radioterapia.
US20020009427A1 (en) 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma
MXPA02009626A (es) 2000-03-31 2003-05-14 Idec Pharma Corp Uso combinado de anticuerpos anti-citocina o antagonistas y anti-cd20 para el tratamiento de linfoma de celulas b.
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
EP1286692A4 (de) 2000-04-25 2004-11-17 Idec Pharma Corp Intrathekale verabreichung von rituximab zur behandlung von lymphomen des zenralen nervensystems
EP1299128A2 (de) 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Kaltes anti-cd20 antikörper/radiomarkiertes anti-cd22 antikörper kombination
SI1296714T1 (sl) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
JP2004502742A (ja) 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
CN1494553A (zh) 2001-01-29 2004-05-05 IDECҩ�﹫˾ 改变的抗体及其使用方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
CN100574803C (zh) 2001-01-31 2009-12-30 拜奥根Idec公司 免疫调节抗体在治疗肿瘤性疾病中的用途
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
JP4679035B2 (ja) 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
AU2002315168A1 (en) 2001-06-14 2003-01-02 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
FR2827636B1 (fr) 2001-07-19 2003-11-28 Eurocopter France Systeme de regulation du regime d'un moteur d'un helicoptere
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
ATE401787T1 (de) 2002-12-16 2008-08-15 Genentech Inc Menschliches cd20 exprimierende transgene mäuse
RS20100366A (sr) 2002-12-16 2011-04-30 Genentech, Inc. Varijante imunoglobulina i njihova upotreba
KR101092171B1 (ko) 2003-04-09 2011-12-13 제넨테크, 인크. Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는환자에서의 자가면역 질환의 치료법
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
AU2004256042A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
CA2532556A1 (en) 2003-07-29 2005-02-24 Genentech, Inc. Assay for human anti cd20 antibodies and uses therefor
US20050053602A1 (en) 2003-08-29 2005-03-10 Genentech, Inc. Therapy of ocular disorders
MXPA06005104A (es) 2003-11-05 2007-01-25 Palingen Inc Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim.
CA2549237A1 (en) 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in transplant rejection
EP1696955A2 (de) 2003-12-19 2006-09-06 Genentech, Inc. Nachweis von cd20 in der therapie von autoimmunkrankheiten
AR049021A1 (es) 2004-04-16 2006-06-21 Genentech Inc Tratamiento de trastornos con un anticuerpo que se une a cd20
AU2005244751A1 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting B cell depletion
RU2006145450A (ru) 2004-04-16 2008-06-27 Дженентек, Инк. (Us) Анализ на антитела
JP2007536246A (ja) 2004-05-05 2007-12-13 ジェネンテック・インコーポレーテッド 自己免疫疾患の予防法
WO2005114218A2 (en) 2004-05-15 2005-12-01 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
RU2396980C2 (ru) 2004-06-04 2010-08-20 Дженентек, Инк. Способ лечения волчанки
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
US20060062787A1 (en) 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
US20060067930A1 (en) 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
CN101087807A (zh) 2004-10-05 2007-12-12 健泰科生物技术公司 治疗血管炎的方法
CA2587932A1 (en) 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
EP1833970A2 (de) 2004-12-22 2007-09-19 Genentech, Inc. Verfahren zur herstellung löslicher, mehrere membranen überspannender proteine
DOP2006000013A (es) 2005-01-13 2006-07-15 Genentech Inc Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
WO2006116369A2 (en) 2005-04-22 2006-11-02 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
AU2006251647A1 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage

Also Published As

Publication number Publication date
CY1105295T1 (el) 2010-03-03
EP1642596A3 (de) 2006-04-12
WO2000067796A1 (en) 2000-11-16
US20140134164A1 (en) 2014-05-15
KR20020027311A (ko) 2002-04-13
US20130084289A1 (en) 2013-04-04
CA2944644A1 (en) 2000-11-16
AU2005200462B2 (en) 2008-08-07
EP1637160A2 (de) 2006-03-22
US8545843B2 (en) 2013-10-01
KR20080039550A (ko) 2008-05-07
US20120201818A1 (en) 2012-08-09
AU2005200462B8 (en) 2009-01-15
JP2014111603A (ja) 2014-06-19
BR0011197A (pt) 2002-02-19
US20160175435A1 (en) 2016-06-23
US20180264107A1 (en) 2018-09-20
JP2010159255A (ja) 2010-07-22
JP2017149726A (ja) 2017-08-31
HUP0201009A2 (en) 2002-07-29
NZ514914A (en) 2004-09-24
PL351962A1 (en) 2003-07-14
US20130273042A1 (en) 2013-10-17
US20110008336A1 (en) 2011-01-13
PL200134B1 (pl) 2008-12-31
CN100358577C (zh) 2008-01-02
US20110008338A1 (en) 2011-01-13
CN1378459A (zh) 2002-11-06
EP1176981A1 (de) 2002-02-06
EP1176981B1 (de) 2005-11-30
JP2018058906A (ja) 2018-04-12
EP1637160A3 (de) 2006-05-03
US20110008250A1 (en) 2011-01-13
CA2372603C (en) 2015-11-17
ATE311199T1 (de) 2005-12-15
JP2002544174A (ja) 2002-12-24
EP1642596A2 (de) 2006-04-05
US9993550B2 (en) 2018-06-12
DK1176981T3 (da) 2006-04-10
ES2254174T3 (es) 2006-06-16
NO20015417D0 (no) 2001-11-06
AU777970B2 (en) 2004-11-04
CA2904259C (en) 2016-11-15
NO20015417L (no) 2002-01-07
CA2372603A1 (en) 2000-11-16
DE60024436D1 (de) 2006-01-05
HK1043312B (en) 2006-07-28
AU2005200462A1 (en) 2005-03-03
JP6143664B2 (ja) 2017-06-07
AU4714300A (en) 2000-11-21
HK1043312A1 (en) 2002-09-13
CA2944644C (en) 2017-08-22
MXPA01011279A (es) 2002-07-02
AU777970C (en) 2006-08-17
US20130330332A1 (en) 2013-12-12
US20110008337A1 (en) 2011-01-13
US7820161B1 (en) 2010-10-26
CA2904259A1 (en) 2000-11-16
DE60024436T2 (de) 2006-08-17

Similar Documents

Publication Publication Date Title
IL146005A0 (en) Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
PT1187632E (pt) Tratamento com anticorpos anti-erbb2
GB9722520D0 (en) Compounds
ZA200305691B (en) The use of substituted azetidione compounds for the treatment of sitosterolemia
DE60037586D1 (de) Zellwachstumsinhibition
GEP20104997B (en) Composition comprising anther2 antibodies
ZA991578B (en) Compounds for the treatment of ischemia.
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
BR9901279A (pt) Triciclicos substituìdos
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ZA9811507B (en) Combination effective for the treatment of impotence.
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
ZA9921B (en) Process to reduce the AOX level of wet strength resins by treatment with base.
PT1389213E (pt) Formulacoes de 3,7-diazabiciclo 3,3,1¿ como compostos antiarritmicos
EA200100854A1 (ru) Кальций-литические соединения
EP1649870A3 (de) Behandlung von Autoimmunkrankheiten mit Antagonisten die Oberflächenmarker von B Zellen binden
IT1308893B1 (it) Carrozzeria grezza per autoveicoli.
EG23255A (en) Floating hydrocarbon treating plant.
GB0103045D0 (en) Organic Compounds
LU90726B1 (fr) Acier h de forte -paisseur de classe 590 mpa ayant une excellente t-nacit- et proc-d- pour le fabriquer
ATE345818T1 (de) S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
BR0007395B1 (pt) compostos de s-nitrosotióis como agentes para o tratamento de disfunções circulatórias.
ZA200301049B (en) Trichoderma Composition.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired